The increasing field of targeted treatment relies heavily on recombinant cytokine technology, and a detailed understanding of individual profiles is absolutely crucial for refining experimental design and therapeutic efficacy. Specifically, examining the characteristics of recombinant IL-1A, IL-1B, IL-2, and IL-3 demonstrates notable differences in